Drug Patents owned by Upjohn

1. List of Lyrica Cr drug patents

LYRICA CR's oppositions filed in EPO
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10022447 UPJOHN Solid pharmaceutical compositions containing pregabalin
Nov, 2026

(3 years from now)

US8945620 UPJOHN Solid pharmaceutical compositions containing pregabalin
Nov, 2026

(3 years from now)

US9144559 UPJOHN Solid pharmaceutical compositions containing pregabalin
Nov, 2026

(3 years from now)

US9144559

(Pediatric)

UPJOHN Solid pharmaceutical compositions containing pregabalin
May, 2027

(4 years from now)

US10022447

(Pediatric)

UPJOHN Solid pharmaceutical compositions containing pregabalin
May, 2027

(4 years from now)

US8945620

(Pediatric)

UPJOHN Solid pharmaceutical compositions containing pregabalin
May, 2027

(4 years from now)

Drugs and Companies using PREGABALIN ingredient

Market Authorisation Date: 11 October, 2017

Treatment: Treatment of postherpetic neuralgia; Treatment of neuropathic pain associated with diabetic peripheral neuropathy

Dosage: TABLET, EXTENDED RELEASE;ORAL

How can I launch a generic of LYRICA CR before it's patent expiration?
More Information on Dosage

LYRICA CR family patents

13

United States

1

Portugal

1

Uruguay

1

Guatemala

1

Spain

1

Brazil

1

Costa Rica

1

IB

1

New Zealand

1

Dominican Republic

1

Norway

1

Argentina

1

Morocco

1

Peru

1

China

1

Taiwan, Province of China

1

Korea, Republic of

1

Hong Kong

1

EA

1

Tunisia

1

South Africa

1

Japan

1

Canada

1

Cyprus

1

Slovenia

1

ME

1

Israel

1

Poland

1

Australia

1

RS

1

Ecuador

1

Denmark

1

Netherlands

1

European Union

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in